Atypical antipsychotics: New drugs, new challenges
Atypical antipsychotics: New drugs, new challenges
复制标题
DOI：
10.3949/ccjm.74.8.597
复制
发表时间：
2007-08-01
影响因子：
6.1
通讯作者：
Muzina, David J.
中科院分区：
文献类型：
--
作者：
Mathews, Manu;Muzina, David J.
与第一代或“典型”抗精神病药物相比，第二代或非典型抗精神病药物引起的锥体外系（运动）问题较少，但它们带来了新的挑战，因为它们经常导致代谢紊乱，如体重增加、高脂血症、胰岛素抵抗和2型糖尿病。服用非典型抗精神病药物的患者应监测血糖和心血管危险因素，并在出现此类问题时接受治疗。
Compared with the first-generation, or "typical" antipsychotic drugs, second-generation or atypical antipsychotics cause fewer extrapyramidal (motor) problems, but they pose new challenges, as they often contribute to metabolic disturbances such as weight gain, hyperlipidemia, insulin resistance, and type 2 diabetes mellitus. Patients taking atypical antipsychotics should be monitored for glycemic and cardiovascular risk factors and should receive treatment for such problems as they arise.